Moderna is a biotechnology company focused on drug discovery, drug development, and vaccine technologies based exclusively on messenger RNA.
Moderna is pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients.
Moderna was founded in Sep 2010, by Robert S. Langer, Derrick Rossi, Timothy A. Springer, Kenneth R. Chien, and Noubar Afeyan. The company is headquartered in Cambridge, MA, witth an office in Norwood, MA.
Moderna's pipeline includes development candidates for mRNA-based vaccines and therapies spanning several therapeutic areas, and we have multiple clinical trials underway with other development candidates progressing toward the clinic.
Moderna has strategic relationships with AstraZeneca, Plc. (AZ), Merck, Inc (MRK) and Vertex Pharmaceuticals (VRTX), as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense; the Biomedical Advanced Research and Development Authority (BARDA) etc.
Moderna is actively working on developing vaccine for COVID-19 disease. They are on Phase 3 study of its mRNA vaccine candidate (mRNA-1273). Moderna is working closely with BARDA and the NIH, including NIAID’s COVID-19 Prevention Network (CoVPN), to conduct the Phase 3 COVE study under the auspices of Operation Warp Speed.
Moderna is backed by Flagship Pioneering, AstraZeneca, Alexion Pharmaceuticals, Viking Global Investors LP, Invus, RA Capital Management, Wellington Management Company, LLP among many others. The company received $472M grant from Biomedical Advanced Research and Development Authority (BARDA) for coronavirus vaccine development. This brings Moderna's total funding to $2.7B to date. The company was last valued at $7B post-money after it had raised a financing in Feb 2018.